Protagonist gains nearly double after FDA removes clinical hold on rusfertide program

Oct. 11, 2021 7:36 AM ETProtagonist Therapeutics, Inc. (PTGX)By: Mamta Mayani, SA News Editor2 Comments

Dollar moving up. Money finance growth chart graph stock market

Aslan Alphan/iStock via Getty Images

  • Protagonist Therapeutics (NASDAQ:PTGX) soars 96.1% premarket after FDA removed the full clinical hold on its rusfertide clinical studies, as announced on September 17, 2021.
  • Per the FDA, dosing in all clinical studies of rusfertide may be resumed.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.